The abstract is read at the publisher; the summary is JClub's.
Paliperidone discontinuation in schizophrenia shows two PANSS relapse trajectories—rapid and delayed—where rapid relapse is linked to higher baseline severity, not discontinuation status.
- Why it matters: Relapse after stopping antipsychotics may reflect either a medication effect or heterogeneous illness courses, but symptom patterns before relapse and how they relate to discontinuation are unclear.
- What they did: A meta-analysis of individual participant data from five randomized, double-blind, placebo-controlled discontinuation trials used latent class mixed modelling of longitudinal PANSS to classify symptom-change trajectories before relapse.
- The result: Rapid relapse occurred at similar rates with continuation versus discontinuation in both LAI and oral paliperidone trials, and symptom profiles at relapse did not differ by discontinuation status; rapid relapse had higher baseline PANSS (p<0·0010).
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.